Abstract:Cardiac hypertrophy is characterized by an increase in cell size in the absence of cell division and is accompanied by a number of qualitative and quantitative changes in gene expression. Most forms of hypertrophy in vivo are compensatory or adaptative responses to increased workload resulting from various physiological and/or pathological etiologies. Until severe pathological alterations become apparent, myocytes show no drastic morphological changes. On the level of gene expression, upregulation of the so-called fetal genes, i.e., beta-myosin heavy chain, alpha-skeletal and alpha-smooth muscle actin, and atrial natriuretic factor (ANF) may be observed concomitant with a downregulation of alpha-myosin heavy chain and the Ca pump of sarcoplasmic reticulum. The use of primary cell culture systems for cardiomyocytes as an in vitro model for the hypertrophic reaction has identified a number of different stimuli as mediators of cardiac myocyte hypertrophy. The molecular dissection of the different intracellular signaling pathways involved herein has uncovered a number of branching points to cytosolic and nuclear targets and has identified many interactions between these pathways. The individual administration of these hypertrophic stimuli, i.e., hormones, cytokines, growth factors, vasoactive peptides, and catecholamines, to cultured cardiomyocytes, reveals that each stimulus induces a distinct phenotype as characterized by gene expression pattern and cellular morphology. Surprisingly, triiodothyronine (T3) and basic fibroblast growth factor (bFGF) effect a similar cellular phenotype although they use completely different intracellular pathways. This phenotype is characterized by drastic inhibition of myofibrillar growth and by upregulation of alpha-smooth muscle actin. On the other hand, insulin-like growth factor (IGF) I, a factor promoting muscle cell differentiation, and bFGF, an inhibitor of differentiation, cause completely different cardiomyocyte phenotypes although both are known to signal via receptor tyrosine kinases and have been shown to activate the Ras-Raf-MEK-MAP kinase pathway. However, both IGF-I and bFGF depend on T3 to bring about their typical responses, i.e., T3 is permissive for the action of these two growth factors on the expression of alpha-smooth muscle actin and cell morphology. Most of the hypertrophic stimuli are balanced under normal circumstances in vivo. When this balance is disturbed, however, a pathological heart phenotype may become dominant. Thus the knowledge of signaling pathways and cellular responses triggered by hypertrophic stimuli may be essential for the implementation of therapeutic strategies in the treatment of cardiac hypertrophy.

Advance of PKC Signaling Pathway in Exercise-induced Cardiac Myocyte Hypertrophy

Role of Mitogen-Activated Protein Kinase in Myocardial Hypertrophy

Protein Kinase C Activation in Cardiac Hypertrophy and Failure

Reverse Effect of Protein Kinase C Inhibitor Ro-31-8220 on the Hypertrophy of Cardiomyocytes of Neonatal Rats Induced by High Glucose Levels

Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway

The signal transduction pathway of PKC/NF-κB/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats

The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats.

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Ca2+—Dependent Signaling Pathways Through Calcineurin and Ca2+ Calmodulin—Dependent Protein Kinase in Development of Cardiac Hypertrophy

PKC Mediates PACSIN2 to Regulate Hypertrophic Cardiomyocytes in the Aggravation of the Compensatory Function

Abstract 72: Pka is A Master Regulator of Pathological Cardiac Hypertrophy

Abstract 18932: Pka is a Master Regulator of Cardiac Hypertrophy Induced by Pressure Overload

Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy

Combined Cardiomyocyte PKCδ and PKCε Gene Deletion Uncovers Their Central Role in Restraining Developmental and Reactive Heart Growth

Casein Kinase-2 Interacting Protein-1 Regulates Physiological Cardiac Hypertrophy via Inhibition of Histone Deacetylase 4 Phosphorylation

Pressure Overload–Mediated Sustained PKR2 (Prokineticin-2 Receptor) Signaling in Cardiomyocytes Contributes to Cardiac Hypertrophy and Endotheliopathies

Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes.

Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy

Abstract 495: The Loss Of Pka Activity And Activation In Cardiomyocytes Does Not Induce Cardiac Abnormalities

mAKAPβ signalosome: A potential target for cardiac hypertrophy

Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes